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Abstract: This study focuses on the prices for laboratory testing services and testing capacity in nine of 
the major European chemicals producing countries. The purpose is to bridge the existing gap of a 
representative study on test prices and the available testing capacity. At the core are seventy-six test 
categories, in particular toxicological and ecotoxicological tests as required by REACH, the EU Chemicals 
Policy Review. The price and capacity information was gathered by a survey of twenty-eight independent and 
corporate laboratories in the second half of 2004. The survey aimed at finding out minimum, average and 
maximum estimates of costs/prices and the available average and maximum testing capacities. The data 
exploration has shown a considerable variability in the prices for single tests. For reasons of completeness an 
overview of the testing cost for a registration according to the four work packages of REACH is provided. 
The most difficult issue was the estimation of average and maximum testing capacities. Surprisingly the large 
laboratories supply with 96.5% the vast amount of the total capacity available for testing chemicals in the nine 
European countries the survey has covered. A complete set of tables and figures representing detailed price 
and capacity information is available upon e-mail request to the author. 
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Introduction 
An effective system of chemicals control in the 
EU calls for very detailed information. Although a 
number of surveys is available no representative 
and detailed survey on testing cost as required 
according to the REACH proposal is at hand. 
Neither is there a survey on the available testing 
capacity in the EU. The most recent study on 
testing cost was published in August 2004 by 
BAuA--the Notification Unit according to the 
Chemicals Act at the Federal Institute for 
Occupational Safety and Health in Germany [1]. 
Their survey is based on the requirements for the 
notification of new chemical substances. The 
notification of new chemical substances in the EU 
requires specific test data to be provided by the 
notifier of the new substance. The testing 
requirements depend on the volume of the 
substance marketed per annum. The EU 
regulation distinguished three main categories, that 
is the “Base Set” of information, “Level 1” data, 
and “Level 2” data [2]. BAuA has tried to 
determine the testing cost for these three 
categories. However, it does not cover the 
complete set of test as required by the REACH 
proposal, which can be seen in appendix 1. A 
current overview of studies on testing costs is 
provided in a study of the German Federal 
Environmental Agency [3]. 
This study is to bridge the gap of a 
representative study on test prices and the 
available testing capacity. The study seeks to 
establish a statistical basis for a standard price for 
the single tests as specified in the REACH 
proposal by exploring the existing price variability. 
For the testing laboratories offering their services 
to a broader market, it is the net price charged to 
their customers. And, for the company labs, the 
standard price is a market-oriented transfer price, 
which they would charge to their internal and 
external customers. Thus, this price comprises 
more than the actual or standard costs of a test. It 
includes all costs associated with the carrying out 
of a test, including rent, overhead, and centrally 
funded costs, as well as a profit margin. Thus, this 
price is a good indicator of the single market price 
for corporate laboratory services. 
This study covers the tests as specified by the 
European Commission in their REACH proposal 
Appendix IV to VIII, dated 29 October 2003 [4]. 
In several cases the original REACH testing 
requirements are not specific. Therefore, we 
consulted a paper by Pedersen et al. [5] and 
experts from the testing laboratories, as well as the 
current literature [6]. This survey focuses on 28 
laboratories and chemical companies in Austria, 
Belgium, Denmark, France, Germany, Italy, the 
Netherlands, Switzerland and the UK.  
In the next section of the article we briefly 
discuss a few methodological issues and describe 
the design of the study. The questionnaire and the 
sampling procedure is described in detail. In 
section three the results are presented and 
discussed. We focus on the variability of prices and 
its causes and the difficulty of quantifying the 
available testing capacity. Section four summarizes 
the major findings. 
Method and data 
Methodological considerations 
We should start with a theoretical remark about 
market prices. The remark is based on 
microeconomic theory [7]. From a microeconomic 
viewpoint the price in a competitive market is 
given, as is the capacity. The market price is the 
price at which demand matches supply. The 
market for laboratory testing services can be 
regarded as a perfectly competitive market since it 
has many buyers and sellers, so that no single 
buyer or seller has a significant impact on price. In 
a perfectly competitive market a single market 
price will usually prevail. In case the market is not 
perfectly competitive different laboratories might 
charge different prices for the same test. This can 
happen when one laboratory is trying to win 
customers from its competitors, or because 
customers have loyalties to laboratories, in which 
case these laboratories can charge higher prices 
than their competitors. 
Market prices are only revealed as the result of 
market transactions. For our study this implies 
checking market transactions regarding laboratory-
testing services for the past several years. This 
procedural consideration was put aside during the 
pilot phase of the study because the laboratories 
could not afford to check for a representative 
sample of past market transactions in order to 
derive prices. The only way forward was to focus 
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on the prices they would charge for their testing 
services. And, it is reasonable to assume that the 
prices for specific laboratory tests will be a good 
indicator for the market price. 
Capacity for testing services is a subtle thing. 
Usually, for most products, long-run supply is 
much more price elastic than short-run supply. 
This because firms face capacity constraints in the 
short run and need time for capacity expansion, 
for example by building new testing facilities and 
hiring qualified staff. It could be that short-run 
capacity rises if prices rise sharply. The available 
capacity is based on the cost function of the 
specific laboratory for single tests and on the 
relationship to the market price. Such a cost 
function is a relationship itself between the cost of 
conducting such tests and the output of a 
laboratory. An important issue is how the 
structural factors of a laboratory affect this 
relationship.  
Estimating the available capacity for testing 
services is difficult and one that is pivotal to the 
survey. Capacity is difficult to quantify for many 
reasons. Nearly all laboratories – be they 
independent or corporate laboratories – provide 
services to several industry sectors. Thus, only the 
total capacity available could be given. Estimation 
of capacity is further complicated by the large 
diversity of studies the laboratories offer. 
Study design and data collection  
The study was designed as a cross-sectional 
survey using a questionnaire. We focused on the 
EU countries with a large share of chemicals 
manufacturing volume and on Switzerland because 
this allowed the study to cover most of the 
independent and corporate laboratories in Europe. 
Therefore the study could produce representative 
results and remain manageable. 
The questionnaire covered five major areas. 
The first column of the questionnaire included the 
numbering of the Appendix of the REACH 
proposal so that the tests were grouped according 
to their subject (see appendix 1). Under the 
column, “Test guidelines”, the OECD and EC test 
guidelines were also quoted. Again, it should be 
mentioned that REACH is not specific in all cases.  
 
The questionnaire included the following 
sections: 
• General questions about the 
company/laboratory 
• Identification of the substance/ 
Information on manufacture and use of 
the substance (3 items) 
• Physical-chemical tests (16 items) 
• Toxicological tests (28 items) 
• Ecotoxicological tests (28 items) 
The survey aimed at finding out minimum, 
average and maximum estimates of costs/prices, 
which were based on costs/prices of the past two 
years. Although one might doubt averages, they do 
reflect a “sensed” underlying distribution. Several 
factors are influencing the distribution. Among 
others these are the properties of the substances to 
be tested, unexpected events during the tests, and 
intermediate results; because they often determine 
the effort and inputs for single tests; and as such 
the costs/prices of these. That is the exact actual 
costs/prices could only be given when details on 
the substance to be tested are known by the 
laboratory. Moreover, the prices for the single tests 
do not include costs for dose range finding and for 
the development of analytical method. 
The capacity to conduct testing as required by 
the REACH proposal is available from both the 
chemical firms and independent testing 
laboratories. The required tests need to be 
conducted in general according to the Principles of 
Good Laboratory Practice (GLP) first published 
by the OECD in 1982 and revised in 1997 [8]. 
This meant for our survey that all prices/costs 
needed to be based on GLP requirements. GLP is 
a quality system covering the organisational 
process and the conditions under which non-
clinical safety and environmental studies are 
planned, performed, monitored, recorded, 
reported and archived. 
The following nine categories show the areas of 
expertise in which laboratories might choose to 
specialise. The category numbers correspond to 
the official GLP numbering of these fields. 
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1. Physical-chemical testing 
 These tests measure physical and chemical 
 properties of substances like melting point, 
 flammability etc. 
2. Toxicity studies 
 These studies assume that tests on animals 
 can be used to evaluate the toxicity effects 
 on humans. Examples are acute toxicity 
 studies (oral, dermal, inhalation) and 
 carcinogenicity studies. 
3. Mutagenicity studies 
 These are studies to explore the gene 
 toxicity of substances, for example gene 
 mutation studies like the Ames test.  
4. Environmental toxicity studies on aquatic 
and terrestrial organisms 
 Examples are short-term acute toxicity 
 studies on daphnia. 
5. Studies on behaviour in water, soil and air; 
bioaccumulation and metabolisation 
 These studies explore whether and how 
 substances remain in the environment. 
 Examples are biodegradability and 
 bioaccumulation studies. 
6. Residue studies 
 They are mainly applied to pesticides. Tests 
 are made for all types of agricultural crops 
 (from corn to hops, fruits and vegetables) 
 as well as long-term soil degradation 
 studies. 
7. Studies on effects on mesocosms and 
natural ecosystems 
 These are very specific studies for 
 pesticides like Pond studies. Artificial 
 ponds are used to test different 
 concentrations of substances.  
8. Analytical and clinical chemistry testing 
 This is a special category to characterize 
 laboratories which provide only the 
 analytical part of testing services from 
 categories 2 to 7. They are dealing mainly 
 with biological materials.  
9. Other studies 
The compliance monitoring is organised at the 
national level. The responsible national agencies 
report on the monitoring results to the OECD 
GLP Office and to the corresponding office at the 
EU Commission. 
The recent lists of GLP laboratories for the 
year 2003 mention that Germany has 159 
laboratories, the UK 128, France and Switzerland 
44 each, the Netherlands 36, and Italy 29. These 
lists include independent labs and corporate labs, 
which all conduct their testing in compliance with 
the GLP Principles. 
We have used the lists of the GLP laboratories 
with their areas of expertise to define the parent 
populations to be considered. Besides the eight 
areas of specialization listed above there are certain 
industry-specific specializations. The products and 
industries the labs are specialized in include 
chemicals, pharmaceuticals, agrochemicals, food, 
biocides and environmental legislation. Thus we 
had to select on a case by case basis those 
laboratories specialized in testing chemicals. Based 
on our knowledge and the knowledge of experts 
we tried to identify all relevant testing capacity for 
chemicals in the surveyed countries. However, the 
approach remains arbitrary, mainly due to a lack of 
more detailed information on the sampled 
population. A disadvantage of this procedure is, 
that it makes no sense to calculate a response rate 
because of the necessary but judgemental selection 
procedure. 
We discussed the issue and the criteria which 
laboratories to include in the survey with experts, 
in particular with the British and German GLP 
Offices. Several laboratories were easily dropped 
according to their name, which suggested a 
business other than chemicals testing. More 
important was a systematic screening of the 
indicated areas of expertise of the GLP 
laboratories. We could exclude the areas 6) residue 
studies, 7) mesocosms and natural ecosystem, 8) 
clinical chemistry (applied for the pharmaceutical 
industry) and 9) other studies. We contacted the 
remaining GLP laboratories by phone and asked 
whether they would like to participate in the 
CEFIC survey. The result was that 51 laboratories 
showed their interest in participating in the survey 
(see table 1). In the end twenty-eight of these 
laboratories responded, of which we could use 
twenty-six in our analysis.  
99
      Journal of Business Chemistry Fleischer September 2007 
         
 
 
© 2007 Institute of Business Administration                                    ISSN 1613-9615  
www.businesschemistry.org 
The prices and capacity we asked for were from 
30 June 2004. The author conducted the survey 
from August to December 2004. This long survey 
period has to do with the interest in including as 
many laboratories as possible. It also took a lot of 
effort for the laboratories to compile the requested 
information. We should mention that all of the 
large independent laboratories from the nine 
participating countries are included, with the 
exception of one.  
We should also mention that there are only a 
few corporate labs remaining in existence; in fact 
we obtained data from only four corporate 
laboratories. There is an ongoing process – but 
seemingly terminated – of phasing-out corporate 
laboratories for toxicological and ecotoxicological 
testing (and also for physical-chemical testing). 
The process could be observed in all the 
participating countries, with the result that few 
corporate labs remain. If we take a representative 
sample of seventeen large European firms which 
are listed in the global top fifty chemical 
companies in 2004 [9] than only four of them still 
have their own significant testing facilities.  
A separate issue is, that the relative number of 
participating corporate labs is considerably lower 
than that of independent labs. This is due to the 
fact, that corporate labs are mainly managing 
regulatory compliance issues using independent 
labs for testing services. These corporate labs 
belong to large chemical firms which keep 
nevertheless the GLP status for their labs, but do 
not provide extensive testing services. This was the 
main reason for them not to participate in our 
survey.   
Results and discussion 
Summary of data and analytic technique 
The data exploration has shown a considerable 
variability in the prices for single tests. Three 
attempts were made to reduce the price variability 
of the sample. The attempts were based on the 
response pattern to the three requested prices. The 
responses show the following pattern of prices 
given: 
• Average price 
• Average, minimum and maximum price 
• Minimum and maximum price (price 
range) 
• Minimum price 
The first and the second responses posed no 
problem for calculating the mean and median of 
the average price. However, the laboratories have 
sometimes chosen for the same reason a different 
response pattern. In cases of a broad range of 
prices for a particular test category some preferred 
All labs Participating labs All participating labs 
Country 
Independent 
Labs 
Corporate 
Labs 
Independent 
Labs 
Corporate 
Labs 
Number Percent 
Germany 14 5 9 2 11 39.3
United Kingdom 7 6 4 0 4 14.3
France 4 1 3 1 4 14.3
Netherlands 2 2 2 1 3 10.7
Italy 3 0 2 0 2 7.1
Austria 1 0 1 0 1 3.6
Belgium 1 1 1 0 1 3.6
Denmark 1 0 1 0 1 3.6
Switzerland 1 2 1 0 1 3.6
Total 34 17 24 4 28 100.0
 
Table 1: Sample of independent and corporate laboratories involved in the survey 
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to give minimum and maximum prices only 
whereas others preferred to give the average price 
instead. The problem was that about a third of the 
respondents gave only the price range or the 
minimum price. This information would be lost in 
a rigid calculation of the mean and median of the 
average price since these respondents would not 
enter in the estimation of the statistical parameters. 
Thus, three options were considered to substitute 
the missing average price: first to use the minimum 
price; second, to use the mean of the minimum 
and the maximum price; and third, to use both of 
these substitutes.  
The reasons not to use these substitutions are 
the same that underlie the respondents’ behaviour. 
The main reason is that there is a strong impact on 
testing costs related to the characteristics of the 
substance to be tested. For a number of tests then, 
no normal average price can be given. In these 
cases only a price range is meaningful. However, 
this depends on the substances a laboratory usually 
tests. And in effect, as the responses show, for 
some labs an average price is still meaningful, 
whereas for others only a price range or a 
minimum price can be determined. 
We have experimented with all three 
approaches to substitute for the missing average 
price. In the end, however, we found no less price 
variability than analysing the original data with a 
number of average prices missing.  
Due to the comparatively small sample size and 
to reasons of comparability we limited the 
following presentation and discussion of the single 
tests to mean and median values. 
Analysis of prices 
An overview of minimum, average and maximum prices: 
Appendix 1 offers an overview of the means of 
the average prices for the single test categories. It 
also shows the number of laboratories that 
provided data on average prices. For the purpose 
of comparison we included the costs as surveyed 
by BAuA [1].   
Min. 
price 
Max. 
price 
Avg. price 
Test categories 
Mean Mean Median Mean 
CV 
(%) 
Ratio 
mean to 
median
v 014 - Development of analytical method 4,567 8,333 2,250 5,239 100 2.3 
vii 5.20 - Viscosity 891 983 600 860 49 1.4 
vi 6.8.1 - Assessment of toxicokinetic  
              behaviour 25,818 74,803 1,823 33,041 218 18.1 
v 7.1.1 -  Short-term acute toxicity study on  
              daphnia 3,386 6,135 3,500 3,742 53 1.1 
v 7.1.3 -  Short-term acute toxicity study on  
              fish 3,949 7,336 3,500 4,193 58 1.2 
vii 7.1.6.1 - Fish early-life stage (FELS)  
                  toxicity test 28,717 47,839 21,000 26,254 60 1.3 
vi 7.3.1 - Adsorption/desorption sceening  
              study(HPLC method) 3,521 2,980 2,600 3,878 96 1.5 
vii 7.3.2 - Bioconcentration in (one) aquatic  
               species,preferably fish 43,873 87,082 28,250 40,333 96 1.4 
vii 7.4.2 - Effects on soil micro-organisms 10,311 7,513 6,913 11,765 81 1.7 
 
Table 2: Selection of test categories with high price variability 
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Price variability and its causes: 
We have measured price variability using two 
statistical parameters--the coefficient of variation 
and the ratio mean to median prices.  
The coefficient of variation expresses the 
standard deviation as a percentage of the sample 
mean. This is useful because we are interested in 
the size of the variation relative to the size of the 
observation. Thus, we can compare the variability 
of a test price with a mean of 800 Euros to one of 
80,000 Euros. The standard deviation alone would 
not allow for this possibility. Furthermore, the 
coefficient of variation is fairly easily understood 
and it incorporates all the relevant data. However, 
there is no general standard for an acceptable level 
of price variability. Thus, we had to fix a 
reasonable boundary. 
The ratio mean to median of a sample of 
observations is a crude measure of the amount of 
variability (dispersion) in the distribution of the 
sample. It is commonly used to measure the skew 
of a distribution. And it is a simple way of 
identifying the test categories with the greatest 
variability in prices. A step-by-step screening has 
led to nine test categories with high price 
variability. Table 2 summarizes the statistical 
properties of these tests. 
The table shows one extreme outlier in the test 
category “Assessment of toxicokinetic behaviour 
(vi 6.8.1)”. Out of the six responding laboratories 
four gave a very low price, one lab gave 7-times 
the median of the average price and the outlier lab 
100-times the median of the average price. One 
possible reason for the majority of prices around 
1,800 Euro might have to do with the actual legal 
requirements. In the OECD-Guideline 417 
respective EU-Guideline B.36 expensive 
experimental testing is applied for a production 
volume beginning with 100 tonnes per annum. 
However the REACH proposal has lowered this 
boundary to 10 tonnes per annum. Thus, the 
majority of the labs might not have considered 
changes in the REACH testing requirements. 
The outlier sheds as well light on three factors, 
which may have caused the variability of the 
prices. First, the prices may not reflect identical 
test offers, that is the products are not 
homogeneous and thus no single market price is 
able to prevail. This possibility could not be 
avoided in our survey because we could not ask 
for data covering the whole set of 30,000 chemical 
substances involved. Second, there are economic 
reasons, which include differences in input factors, 
efficiency of the laboratories, product portfolio 
and size, etc. Third, there is a miscellaneous 
category of reasons, such as differences in physical 
locations, that is when geographical differences are 
likely to lead to structural differences. E.g. 
laboratories which are located in areas heavily 
concentrated with firms of the chemical industry 
might have different demands for their testing 
services than laboratories in less concentrated 
areas. We discuss how these factors might have 
influenced the established price variability 
immediately below. An example of a test category 
with high price variability is “the acute toxicity 
study on daphnia”. Figure 1 shows the distribution 
of average prices as a histogram. This test uses 
daphnia which are small crustaceans, about 0.2 to 
5 mm in length. They are used because they 
exhibit consistent responses to toxins in water. 
They are simple to be produced in large number. 
However, there are differences to do this as well as 
in the application of the experimental testing 
design. Figure 1 shows these differences and 
shows a price advantage of the small labs. The 
most obvious reason for price variability is that the 
properties of the specific test categories as outlined 
in our questionnaire were not perceived as 
unambiguous. The test categories left room for 
interpretation and diversity. The nine test 
categories in Table 2 illustrate that the prices 
surveyed may include different testing methods 
and services. We have tried to avoid this 
systematic bias by indicating the respective OECD 
and EU testing guidelines in the questionnaire. 
However, the testing guidelines themselves include 
a variety of testing options, which have 
implications on the cost of the overall test to be 
undertaken for a specific substance.  
We should now consider the second reason for 
price variability, which has to do with economic 
factors. Among the few important economic 
determinants of cost are: size of the laboratory, 
prices of input factors (labour and materials), rate 
of output (i.e., utilization of fixed laboratory 
personnel and equipment), quality of input factors, 
size of the testing lots, laboratory technology, and 
the organization of the laboratory. One 
determinant on which we have information is the 
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size of the laboratories. Our sample size is not 
large enough to test for differences in price means. 
We can, however, take a look at the actual 
differences in prices subdivided by size-classes. 
And a size-class distribution, which divides our 
sample well, is if we define “small labs” as having 
1 to 100 employees and “large labs” as having 
more than 100.   
We have tested for the difference in the means 
of the average price using only the small and large 
labs. We applied a Mann-Whitney U-test for the 
average price of 76 tests. In one case (1.3%) no lab 
offered the test and in eight cases small labs did 
not offer the tests (10.5%). In five cases (6.6%) we 
found a significant statistical difference in the 
averages prices between small and large labs at a 
5%-level of significance. However, for the large 
majority of test categories, that is for 62 cases 
(81.6%) we found no significant statistical 
difference at the 5%-level in the in the price 
offered by small and large labs.  
There are three points that we should mention. 
First, the small labs are not really that small. They 
average thirty-one employees. In comparison, the 
large labs average 386 employees (if we exclude 
one very large lab). The size of the small labs 
might be related to comparative advantage. E.g. 
the price advantages of the small labs might be due 
to advantages of specialization. Small labs generally 
offer a limited package of tests, which might 
enable them not to incur high fixed-costs. Second, 
we have no indication that the small labs have 
responded strategically, that is that they have 
responded to us with lower prices then they 
usually would charge. Third, the small labs supply 
on average only 3.5% of the overall capacity for 
testing services, for two thirds of the required tests 
the large labs supply the entire testing capacity. 
Due to this fact we have not explicitly included the 
mean values of the small labs into the estimation 
of testing costs for work packages according to 
REACH. However, they are implicitly included 
because we use the mean values for “All labs”, 
which the small labs have a strong impact on. 
Estimation of testing costs for work packages: 
For reasons of completeness we provide an 
overview of the testing cost for a registration 
according to the four work packages of REACH. 
The estimation used the mean values of the 
average and maximum prices for the single tests. 
The test categories are specified in the Appendix V 
to VIII of the REACH proposal of October 2003. 
The estimated test costs can be adjusted for special 
cases. We have added an estimated amount of 
costs for the development of analytical methods 
for the single work packages. The amounts are 
20,000 Euros for 10-100t/y, 40,000 Euros for 100-
1000t/y and 50,000 for >1000 t/y. It should be 
mentioned that the cost for the development of 
analytical method can vary enormously. The 
important point is, that our survey provides a very 
detailed and reliable source for actual prices for 
GLP testing services.  
For our estimation of package prices we used, 
so to speak, three scenarios. First, the mean value 
of average prices of all labs and second, the one 
for the large labs. The former provides the low 
price level due to the relative low prices of the 
small labs it includes. The third scenario is based 
on the mean value of the maximum prices of all 
labs. The reason that in case of work package 
“100-1000 t/y” the maximum price is lower than 
the average price is that both price means include 
0
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v 7.1.1 pa Short-term toxicity study on daphnia: avg. price
 
V 7.1.1 – Acute toxicity study on daphnia 
Type of lab N Avg. price: 
Mean in Euros 
All labs 13 3,742 
Small labs 5 2,330 
Large labs 4 4,900 
Corporate labs 4 4,350 
 
Figure 1: Analysis of a test category with high 
price variability 
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partly different labs with a different response 
pattern. 
Analysis of capacity 
Difficulty in quantifying capacity: 
Laboratories which could perform the tests as 
specified in the REACH proposal belong to 
subgroups of the main group “74.30 Technical 
testing” of the European classification of 
economic activities, NACE. The subgroups are:  
• 74.30.1 Engineering control and analysis,  
• 74.30.2 Physical testing and analysis and  
• 74.30.3 Chemical testing and analysis.  
However, most of the Statistical Offices of the 
European Member States have only recently begun 
to collect information on this service sector, and 
they provide – if at all – only data for the main 
group 74.30.  
To our knowledge and based on data 
downloaded from the Eurostat database in 
February 2005 we can conclude that statistical data 
on employment, cost, sales and the size 
distribution of laboratories since the year 2000 is 
only available for Germany and Italy for NACE 
74.30. Thus, we cannot use official statistics for 
the purposes of our study. Furthermore, this data 
is too unspecific for estimating the available 
capacity for single tests. At best it could give a clue 
to make a guess about the overall laboratory 
capacity in the EU.  
We have sampled the laboratories for 
participation in this survey based on whether they 
perform testing according to GLP. This basis for 
the sampling of the laboratories has led to a quite 
representative picture of the overall testing 
capacity for industrial chemicals. This is because all 
of the large laboratories have responded to our 
questionnaire, except one lab in the UK, which 
primarily conducts pre-clinical studies for the 
pharmaceutical industry. Nearly all of the medium-
sized and small labs – from Belgium, France, 
Germany, Italy and the Netherlands – which 
provide testing services for the chemical industry 
are included.  
Note that only very few of the labs with GLP 
status work for the chemical industry. We estimate 
that the share is less than 10%. Furthermore, we 
have included nearly all of the corporate labs. As 
already mentioned there are very few corporate 
laboratories left. The capacity estimation and 
questions we asked the laboratories were based on 
the following considerations. 
Laboratory capacity is the capability to perform 
tests according to professional standards or 
guidelines. From an economic perspective the 
capacity of a laboratory for testing chemical 
substances represents the rate of operation that 
will yield the minimum average total cost of tests. 
Capacity in this sense is not fixed, but will vary 
with changes in the costs of the factors of 
conducting the tests. Capacity can be regarded as 
being optimal when a situation is achieved at 
which cost per unit of test is minimized.  
The estimations of average and maximum 
testing capacities are still very difficult because 
they depend on a number of boundary conditions 
which impact on capacity management. It is 
particularly difficult for large laboratories with high 
capacity, which provide services to a number of 
industry sectors. Capacity is further complicated by 
the large diversity of studies they offer. 
It is important to recognize that the maximum 
number of test per annum is the total theoretical 
capacity of a laboratory for each single test/study 
 1-10 t/y  10-100 t/y 100-1000 t/y >1000 t/y 
Average price, all labs 56,360 279,838 799,562 1,582,616 
Average price, large labs 70,407 292,269 916,340 1,610,910 
Maximum price, all labs 81,120 409,602 872,724 1,966,189 
 
Table 3: Summary of the estimated test costs for work packages of REACH Appendix V-VIII (in Euros 
per substance) 
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type considering no other studies in the same 
category. Hence, the actual number of studies 
conducted – that is the average testing capacity – 
does not reach the maximum number but depends 
on the number of other tests of the same category 
and may vary considerably from year to year. 
Laboratory management might imply short-
term shifting of capacity from one test category to 
another or from one department to another; 
however, it does not increase capacity itself. We 
estimate that about one-half of the laboratory 
capacity might be shifted during short-term 
capacity adjustment. 
For all these reasons, we have asked the labs to 
consider an estimation of the average and 
maximum number of tests based on the number 
of tests that they are able to conduct per year, as 
well as the number of tests they conducted in the 
past one or two years. The critical question 
certainly concerns the average capacity since this 
knowledge is needed to determine the number of 
studies the labs could reasonably run 
No. of REACH appendix and test category 
No. of 
labs 
Total avg. 
capacity 
viii 7.4.5    -  Long-term toxicity testing on soil invertebrates 2 6 
viii 7.6       -  Long-term or reproductive toxicity to birds: 3 9 
vi 6.7.2      -  Developmental toxicity study (rabbits), oral gavage 3 12 
vii 7.2.1.4   -  Sediment simulation testing (for substances adsorbing to sediment) 6 12 
viii 7.4.6     -  Long-term toxicity testing on plants 2 12 
viii 7.4.4     -  Long-term toxicity testing on earthworms 7 16 
vii 7.3.2      -  Bioconcentration in (one) aquatic species, preferably fish 8 19 
vii 7.4.2      -  Effects on soil micro-organisms 7 19 
vi 6.6.1b     -  Short-term repeated dose tox.: 28 days, inhalation (rats) 8 21 
viii 6.6.3      -  Long-term repeated dose tox. study (longer than 12 month) 10 21 
vii 7.4.3       -  Short-term toxicity testing on plants 6 25 
vi 6.4.2        -  In vitro cytogenicity study in mammalian cells (MNT) 3 28 
vii 6.7.3        -  Two-generation reproduction tox. study, oral gavage 11 28 
viii 6.9          -  Carcinogenicity study (rats) 11 29 
vii 7.2.1.3     - Soil simulation testing (for substances adsorbing to soil) 7 29 
viii 7.5          -  Long-term toxicity testing on sediment organisms 6 30 
 
Table 5: The 16 test categories with the lowest average annual test capacity in the major European 
chemicals producing countries  
No. of required test packages based on 282 
substances p.a. Required test 
package 
Range of 
annual volume 
in tonne/year 
Share of the total 
number of 
substances (%) EU capacity (excl. an 
import share of 53%) 
EU capacity and 
Switzerland 
Base set 1-10 57.8 77 98 
Level 1a 10-100 8.5 11 14 
Level 1b 100-1000 2.9 4 5 
Level 2 >1000 0.6 1 1 
 
Table 4: Estimation of the annual overall testing capacity according to the test packages for the 
notification of new chemical substances  
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simultaneously over the course of one year. 
Furthermore, the labs need to be able to provide 
analytical backup for all these studies at the same 
speed as the in vivo part of the study and their 
capacity to do this currently would depend on the 
availability of the methods and the ease of set up. 
Estimation of testing capacity: 
To estimate the available testing capacity we 
used the information collected with our survey on 
average and maximum capacity. We estimated the 
overall capacity for the tests as required by 
REACH by totalling all the capacities of the 
individual laboratories. The information was 
collected for each test category, so that we could 
draw a very detailed picture concerning the overall 
capacity for single tests for the nine countries we 
have surveyed.  
The data on the number of notifications of new 
chemical substances and their structural 
composition may be regarded as one proxy for the 
overall capacity in the EU for the testing of 
industrial chemicals. From the Website of the 
ECB, the European Chemicals Bureau in Ispra 
[10], we received the following statistical 
information summarized in Table 4. 
Since 1994, an annual average of 282 new 
chemical substances has been notified. This 
average is based on the total number of new 
chemical substances. It includes imported 
chemicals to be notified, particularly from the USA 
(22%), Japan (18%) and Switzerland (13%). From 
the overall average of 282 substances we can 
attribute 47% to the testing capacity in the EU. 
For the EU and Switzerland this would be a share 
of 60%. 
This number of test packages to be performed 
annually is obviously a lower bound and compared 
to our capacity figures very low. We have 
summarized the average and maximum testing 
capacity in appendix 2. The ratio of the maximum 
capacity to the average capacity available is about 
2.5. Again, this indicates that the average capacity 
is a good indicator for the available testing capacity 
in the major European chemicals producing 
countries since it is reasonably lower than the 
surveyed maximum capacity. Appendix 2 also 
shows the average capacity for small and large labs. 
The maximum capacity is given for all labs. 
A final consideration regarding available 
capacity should be stated. This has to do with the 
question of whether there might be severe 
bottlenecks for certain testing services. If we order 
the test categories beginning with the lowest 
average annual testing capacity we obtain the 
following picture.  
Among these sixteen test categories with an 
average capacity of thirty or less tests per annum 
are three which already belong to the REACH 
Appendix VI testing package for 10-100 t/y, that 
is, where a considerable number would have to be 
undertaken if the REACH proposal would come 
into force. Six test categories belong to Appendix 
VII (100-1000 t/y) and seven to Appendix VIII 
with more than 1000 p.a. It is obvious that the 
actual testing capacity would become a bottleneck 
when REACH is implemented. 
Conclusion 
This study provides a contribution to the 
empirical foundation of the variability of prices for 
laboratory testing services. The analysis 
emphasizes many important questions related to 
competition in this segment of the service sector. 
In addition, statistical information is provided on 
the supply side of this sector, that is, information 
on the testing capacity in nine of the major 
European chemicals producing countries is given. 
Below is a very short summary of the major results 
and suggestions for further study. 
1. The data exploration has shown a 
considerable variability in the prices for 
single tests and the impact of three factors 
causing this variability. 
2. The first factor that has caused this 
variability is that the properties of the 
specific test categories as outlined in our 
questionnaire were not perceived as 
unambiguous. 
3. The second factor is a bundle of economic 
determinants including differences in input 
factors and the size of the laboratories. A 
surprising result is that laboratories with 
100 or less employees provide their testing 
services at a lower price level. However, 
this result is statistically not significant. It 
seems to be that small laboratories can 
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already achieve economies of scale in 
providing testing services by specialising in 
a limited portfolio of test categories. The 
large laboratories instead have to carry a 
substantial burden of fixed-cost due to 
their full-range testing portfolio. 
4. In order to be complete an overview of the 
testing cost for registration according to 
the four work packages of REACH is 
given in Table 3. 
5. The most difficult issue was the estimation 
of average and maximum testing capacities 
since they depend on a number of 
important factors, particularly on the 
portfolio of the offered and ongoing tests. 
Nevertheless, data on the available capacity 
for the testing of industrial chemicals is 
provided. 
6. The large laboratories (defined as 
laboratories with more than 100 
employees) supply 96.5% of the total 
capacity available for testing chemicals in 
the nine European countries the survey has 
covered. 
For further study four suggestions should be 
considered. First, to increase the understanding of 
competition in this part of the service sector, 
particularly the understanding of the price 
variability and capacity supply by GLP 
laboratories, it is necessary to go into much more 
detail concerning the cost structure and the 
determinants of testing cost. This would imply 
considerably increasing the number of test 
categories over the seventy-six that we have used. 
Second, the range of testing cost is partly 
determined by the properties of the chemical 
substance to be tested. If a typology of substances 
could be developed to allow the clustering of 
chemicals according to testing relevant properties, 
then cost functions for testing cost could be 
constructed to derive more precise testing cost 
estimations. Third, the same applies to the 
development of analytical methods to be able to 
conduct the tests. Finally, the EU needs to further 
develop is official statistics covering the service 
sector. There is no excuse for the lack of detail in 
comparable industry sectors, particularly better 
data for NACE group 74.30.3 “Chemical testing 
and analysis” is needed. More detailed statistical 
data at this level would allow improved capacity 
estimations. 
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Appendix 
Appendix 1: Average prices for the tests as required by the REACH proposal: Overview by size of 
laboratory 
Avg. price: means in Euros 
Tests as specified in Appendix V-VIII of 
the REACH proposal 
Test 
guide-
lines: 
OECD 
/ EU 
No. of 
all 
labs All labs 
Large 
labs 
BAuA 
(2004) 
labs 
Large 
lab share 
of tot. 
capacity 
(%) 
v 011     -  Spectral data  10 2,094 2,626  40 
v 012     -  Analytical characterization  8 2,554 2,294  48 
v 014     -  Development of analytical method  9 5,239 9,500  85 
v 5.02    -  Melting point 102 / A.1 12 674 848 600 71 
v 5.03    -  Boiling point 103 / A.2 12 719 905 600 71 
v 5.04    -  Relative density 109 / A.3 11 657 829 600 72 
v 5.05    -  Vapour pressure 104 / A.4 8 2,779 3,211  84 
v 5.06    -  Surface tension 115 12 817 976 800 70 
v 5.07    -  Water solubility 105 11 3,813 4,508 3,900 78 
v 5.08    -  Partition coefficient 117 & 107 10 3,248 4,034 3,000 76 
v 5.09    -  Flash-point A.9 11 809 896 800 75 
v 5.10    -  Flammability A.10 9 812 912  77 
v 5.11    -  Explosive properties A.14 9 2,284 1,885 3,300 76 
v 5.12    -  Self-iginition temperature A.15 or 16 9 1,338 1,646 1,800 82 
v 5.13    -  Oxidising properties A.17 9 2,144 2,611 2,700 74 
v 5.14    -  Granulometry ECB Guidel. 6 1,328 1,318  92 
vii 5.18  -  Stability in organic solvents 105 5 3,496 4,427  76 
vii 5.19  -  Dissociation constant 112 8 3,216 4,663  76 
vii 5.20  -  Viscosity 114 7 860 1,281  66 
v 6.1      -  In vitro skin irritation/corrosion 430 & 431 4 1,645 1,893  98 
vi 6.1.1  -  In vivo skin irritation/corrosion 404 10 1,194 1,494 1,200 83 
v 6.2      -  In vitro eye irritation/corrosion  4 1,615 1,615  100 
vi 6.2.1  -  In vivo eye irritation/corrosion 405 12 1,343 1,650 1,100 86 
v 6.3      -  Skin sensitisation (LLNA) 406 8 3,959 4,668 3,200 88 
v 6.4.1   -  In vitro gene mutation study (Ames 
test)  11 3,174 3,204 2,900 91 
vi 6.4.2  -  In vitro cytogenicity study in  
mammalian cells (CA) 473 11 19,161 19,217 15,000 86 
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vi 6.4.2  -  In vitro cytogenicity study in 
mammalian cells (MNT) 473 2 11,000 6,000  100 
vi 6.4.3  -  In vitro gene mut. study in mammal. 
cells (MLA) 476 7 16,603 15,644  98 
vi 6.4.3  -  In vitro gene mut. study in mammal. 
cells (HPRT) 476 6 17,283 17,933 13,000 86 
vii 6.4     -  Mouse micronucleus assay 474 9 11,268 11,785 11,000 90 
viii 6.4.4 -  Further in vivo mutagen.study: 
micronucleus or UDS test  4 18,898 21,864 22,000 100 
vi 6.5.1   -  Acute toxicity, oral route (rats) 423 10 1,474 1,639 1,400 79 
vi 6.5.2   -  Acute toxicity, inhalation route 
(rats) 403 / B.2 5 11,734 11,151 9,600 97 
vi 6.5.3   -  Acute toxicity, dermal route (rats) 402 10 2,011 2,470 2,000 88 
vi 6.6.1a -  Short-term repeated dose toxicity: 
28 days, oral  (rats) 407 10 49,390 55,360 40,600 89 
vi 6.6.1b -  Short-term repeated dose tox.: 28 
days, inhalation (rats) 412 5 105,455 99,092 71,700 95 
vii 6.6.1c -  Further short-term repeated dose 
tox.: 28 days, dermal (rabbit) 410 6 49,550 48,175  93 
vii 6.6.1d -  Further short-term repeated dose 
tox.: 28 days, inhalation  1 99,000 99,000  100 
vii 6.6.2   -  Sub-chronic repeated dose tox. 
study: 90 days, oral  (rats) 408 8 115,656 119,450 110,000 92 
viii 6.6.3  -  Long-term repeated dose tox. study 
(longer than 12 month)  6 372,000 382,500 394,000 90 
vi 6.7.1    -  Screening for 
reproduction/developmental tox.(rats) 421 8 54,597 54,129  96 
vi 6.7.2    -  Developmental toxicity study 
(rats), oral gavage e.g. 414 7 63,100 76,550 68,000 93 
vi 6.7.2    -  Developmental toxicity study 
(rabbits), oral gavage e.g. 414 2 92,500 .  67 
vii 6.7.3   -  Two-generation reproduction tox. 
study, oral gavage 416 8 327,975 313,967 250,000 93 
vi 6.8.1    -  Assessment of toxicokinetic 
behaviour  6 33,041 49,161 76,000 90 
viii 6.8.2  -  Further studies on toxicity of 
particular concern  2 101,250 101,250  100 
viii 6.9     -  Carcinogenicity study (rats) 451 7 780,357 787,083 767,000 97 
v 7.1.1     -  Short-term acute toxicity study on 
daphnia 
202 / 
C.2 13 3,742 4,900 5,400 69 
v 7.1.2     -  Growth inhibition study on algae 201 / C.3 14 4,510 5,841 5,700 72 
v 7.1.3     -  Short-term acute toxicity study on 
fish 
203 / 
C.1 12 4,193 6,203 6,100 75 
v 7.1.4     -  Activated sludge respiration 
inhibition testing 
209 / 
L133 12 2,215 3,087 2,300 73 
vii 7.1.5   -  Long-term toxicity study on 
daphnia, 21 days 211 13 13,426 18,092 11,000 74 
vii 7.1.6   -  Long-term toxicity study on fish e.g. 204 8 9,319 12,018  77 
vii 7.1.6.1-  Fish early-life stage (FELS) toxicity 
test 210 11 26,254 30,823 39,000 54 
vii 7.1.6.2-  Fish short-term tox. test on 212 7 10,238 27,413  21 
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embryo & sac-fry stages 
vii 7.1.6.3-  Fish, juvenile growth test 215 8 16,462 21,466  91 
vi 7.2.1.1 -  Ready biodegradability 301 14 3,901 4,803 4,800 64 
vii 7.2.1.2 - Simul. test. on ultimate degrad. in 
surface water 302 6 6,342 5,813 4,000 39 
vii 7.2.1.3 - Soil simulation testing (for subst. 
adsorbing to soil)  6 35,792 43,583  76 
vii 7.2.1.4 - Sediment simulat. test. (for subst. 
adsorb. to sedim.)  5 46,250 41,083  75 
viii 7.2.1.5- Further studies on confirmatory 
biodegration rates 303A 4 17,325 40,000 20,000 72 
vi 7.2.2.1  - Abiotic degradation: Hydrolysis as 
a function of pH C.7 13 6,573 7,032 9,200 92 
vii 7.2.3    - Identification of degradation 
products  1 2,000 .  100 
vi 7.3.1     - Adsorption/desorption sceening 
study (HPLC method) 121 12 3,878 5,187 2,200 89 
vii 7.3.2    - Bioconcentration in (one) aquatic 
species, preferably fish 305 6 40,333 112,500 122,000 74 
vii 7.3.3   -  Further studies on 
adsorption/desorption  7 19,634 26,060 20,200 78 
viii 7.3.4  -  Further environmental fate and 
behaviour studies  1 97,500 97,500  100 
vii 7.4.1   -  Short-term toxicity testing on 
earthworms 
207 / 
L133 11 4,160 4,491 4,000 61 
vii 7.4.2   -  Effects on soil micro-organisms ISO 11267 6 11,765 18,263  74 
vii 7.4.3   -  Short-term toxicity testing on 
plants 208 5 7,565 10,988 8,000 36 
viii 7.4.4  -  Long-term toxicity testing on 
earthworms 
ISO 
11268-2 6 8,580 6,289  56 
viii 7.4.5  -  Long-term toxicity testing on soil 
invertebrates  2 8,574 10,148  17 
viii 7.4.6  -  Long-term toxicity testing on 
plants  0 . .  100 
viii 7.5     -  Long-term toxicity testing on 
sediment organisms  5 14,966 17,776  73 
viii 7.6     -  Long-term or reproductive toxicity 
to birds: 206 3 96,167 79,500  100 
vii 9.        -  Descript. of the analyt. methods of 
detect. and analysis  1 750 750  100 
                -  Vapour pressure, calculation        1,400   
                -  Vapour pressure, static, others        3,000   
                -  Vapour pressure, gas saturation        4,900   
                -  Flammability (solids)        600   
                -  Flammability (contact with water)        1,100   
                -  Subchronic inhalative, EU B.29         198,000   
                -  Fertility one generation, EU B.34         124,000   
                -  Metabolism study, OECD 417         150,000   
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Appendix 2: Average and maximum testing capacity of small and large laboratories (in units of test per 
annum) 
Avg. capacity 
Max. 
capacity
Small 
labs
Large 
labs 
All labs All labsTests as specified in Appendix V-VIII of the 
REACH proposal 
Test 
guide-
lines: 
OECD 
/ EU 
Total Total N Total 
Large 
lab share 
of tot. 
capacity 
(%) N Total
v 011     -  Spectral data  429 285 7 714 40 9 1,197
v 012     -  Analytical characterization  269 250 8 519 48 8 855 
v 014     -  Development of analytical method  47 272 8 319 85 10 644 
v 5.02    -  Melting point 102 / 
A.1 190 462 12 652 71 13 1,168
v 5.03    -  Boiling point 103 / 
A.2 190 462 12 652 71 13 1,168
v 5.04    -  Relative density 109 / 
A.3 180 457 11 637 72 13 1,393
v 5.05    -  Vapour pressure 104 / 
A.4 65 331 9 396 84 10 730 
v 5.06    -  Surface tension 115 196 452 12 648 70 14 1,423
v 5.07    -  Water solubility 105 100 372 14 474 78 15 849 
v 5.08    -  Partition coefficient 117 & 
107 113 372 14 487 76 15 857 
v 5.09    -  Flash-point A.9 135 403 12 538 75 14 1,333
v 5.10    -  Flammability A.10 128 417 12 545 77 13 1,158
v 5.11    -  Explosive properties A.14 72 230 11 302 76 12 680 
v 5.12    -  Self-iginition temperature A.15 or 
16 92 428 11 520 82 12 1,125
v 5.13    -  Oxidising properties A.17 81 234 11 315 74 12 1,003
v 5.14    -  Granulometry ECB 
Guidel. 31 360 7 391 92 6 470 
vii 5.18  -  Stability in organic solvents 105 21 66 6 87 76 7 515 
vii 5.19  -  Dissociation constant 112 61 192 9 253 76 10 695 
vii 5.20  -  Viscosity 114 135 265 8 400 66 10 968 
v 6.1      -  In vitro skin irritation/corrosion 430 & 
431 10 464 8 474 98 9 1,278
vi 6.1.1  -  In vivo skin irritation/corrosion 404 145 698 12 843 83 13 2,028
v 6.2      -  In vitro eye irritation/corrosion  . 425 7 425 100 9 1,138
vi 6.2.1  -  In vivo eye irritation/corrosion 405 140 843 13 983 86 14 2,173
v 6.3      -  Skin sensitisation (LLNA) 406 110 839 12 949 88 13 1,969
v 6.4.1   -  In vitro gene mutation study (Ames test)  110 1,176 13 1,286 91 14 2,638
vi 6.4.2  -  In vitro cytogenicity study in mammalian cells 
(CA) 473 35 224 12 259 86 13 464 
vi 6.4.2  -  In vitro cytogenicity study in mammalian cells 
(MNT) 473 . 28 3 28 100 3 40 
vi 6.4.3  -  In vitro gene mut. study in mammal. cells 
(MLA) 476 4 171 9 175 98 9 374 
vi 6.4.3  -  In vitro gene mut. study in mammal. cells 
(HPRT) 476 7 44 6 51 86 6 59 
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vii 6.4     -  Mouse micronucleus assay 474 19 165 11 184 90 12 337 
viii 6.4.4 -  Further in vivo mutagen.study: micronucleus 
or UDS test  . 76 6 76 100 6 116 
vi 6.5.1   -  Acute toxicity, oral route (rats) 423 250 942 13 1,192 79 14 2,692
vi 6.5.2   -  Acute toxicity, inhalation route (rats) 403 / 
B.2 6 180 9 186 97 10 394 
vi 6.5.3   -  Acute toxicity, dermal route (rats) 402 70 505 13 575 88 14 1,670
vi 6.6.1a -  Short-term repeated dose toxicity: 28 days, 
oral  (rats) 407 31 262 13 293 89 14 460 
vi 6.6.1b -  Short-term repeated dose tox.: 28 days, 
inhalation (rats) 412 1 20 8 21 95 9 64 
vii 6.6.1c -  Further short-term repeated dose tox.: 28 
days, dermal (rabbit) 410 2 26 10 28 93 11 161 
vii 6.6.1d -  Further short-term repeated dose tox.: 28 
days, inhalation  . 6 2 6 100 2 10 
vii 6.6.2   -  Sub-chronic repeated dose tox. study: 90 
days, oral  (rats) 408 13 154 12 167 92 13 251 
viii 6.6.3  -  Long-term repeated dose tox. study (longer 
than 12 month)  2 19 10 21 90 11 66 
vi 6.7.1    -  Screening for reproduction/developmental 
tox.(rats) 421 3 65 11 68 96 12 132 
vi 6.7.2    -  Developmental toxicity study (rats), oral 
gavage e.g. 414 6 86 12 92 93 13 165 
vi 6.7.2    -  Developmental toxicity study (rabbits), oral 
gavage e.g. 414 4 8 3 12 67 3 22 
vii 6.7.3   -  Two-generation reproduction tox. study, 
oral gavage 416 2 26 11 28 93 12 59 
vi 6.8.1    -  Assessment of toxicokinetic behaviour  20 177 6 197 90 6 388 
viii 6.8.2  -  Further studies on toxicity of particular 
concern  . 26 5 26 100 6 147 
viii 6.9     -  Carcinogenicity study (rats) 451 1 28 11 29 97 12 57 
v 7.1.1     -  Short-term acute toxicity study on daphnia 202 / 
C.2 143 368 14 536 69 16 1,290
v 7.1.2     -  Growth inhibition study on algae 201 / 
C.3 122 360 15 497 72 16 1,091
v 7.1.3     -  Short-term acute toxicity study on fish 203 / 
C.1 108 387 15 515 75 17 1,096
v 7.1.4     -  Activated sludge respiration inhibition 
testing 
209 / 
L133 83 233 14 318 73 15 774 
vii 7.1.5   -  Long-term toxicity study on daphnia, 21 
days 211 23 80 13 108 74 14 236 
vii 7.1.6   -  Long-term toxicity study on fish e.g. 204 17 57 11 74 77 12 194 
vii 7.1.6.1-  Fish early-life stage (FELS) toxicity test 210 14 20 12 37 54 13 126 
vii 7.1.6.2-  Fish short-term tox. test on embryo & sac-
fry stages 212 25 7 10 33 21 11 137 
vii 7.1.6.3-  Fish, juvenile growth test 215 3 30 9 33 91 10 100 
vi 7.2.1.1 -  Ready biodegradability 301 167 317 14 496 64 17 1,169
vii 7.2.1.2 - Simul. test. on ultimate degrad. in surface 
water 302 25 16 6 41 39 7 172 
vii 7.2.1.3 - Soil simulation testing (for subst. adsorbing 
to soil)  2 22 7 29 76 7 61 
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vii 7.2.1.4 - Sediment simulat. test. (for subst. adsorb. to 
sedim.)  1 9 6 12 75 6 30 
viii 7.2.1.5- Further studies on confirmatory 
biodegration rates 303A 13 34 6 47 72 7 193 
vi 7.2.2.1  - Abiotic degradation: Hydrolysis as a 
function of pH C.7 30 361 15 393 92 16 681 
vii 7.2.3    - Identification of degradation products  . 55 3 55 100 4 108 
vi 7.3.1     - Adsorption/desorption sceening study 
(HPLC method) 121 40 318 13 358 89 14 560 
vii 7.3.2    - Bioconcentration in (one) aquatic species, 
preferably fish 305 4 14 8 19 74 10 62 
vii 7.3.3   -  Further studies on adsorption/desorption  20 81 8 104 78 8 172 
viii 7.3.4  -  Further environmental fate and behaviour 
studies  . 20 2 20 100 2 35 
vii 7.4.1   -  Short-term toxicity testing on earthworms 207 / 
L133 26 41 10 67 61 12 283 
vii 7.4.2   -  Effects on soil micro-organisms ISO 
11267 3 14 7 19 74 8 91 
vii 7.4.3   -  Short-term toxicity testing on plants 208 16 9 6 25 36 8 77 
viii 7.4.4  -  Long-term toxicity testing on earthworms ISO 
11268-2 7 9 7 16 56 10 111 
viii 7.4.5  -  Long-term toxicity testing on soil 
invertebrates  . 1 2 6 17 3 75 
viii 7.4.6  -  Long-term toxicity testing on plants  . 12 2 12 100 2 25 
viii 7.5     -  Long-term toxicity testing on sediment 
organisms  3 22 6 30 73 7 80 
viii 7.6     -  Long-term or reproductive toxicity to birds: 206 . 9 3 9 100 5 116 
vii 9.        -  Descript. of the analyt. methods of detect. 
and analysis  . 1 1 1 100 2 60 
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